An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Adial Pharmaceuticals, a clinical-stage biopharmaceutical company, has been granted a key patent by the United States Patent and Trademark Office. The patent covers the combination of the Company's genetic diagnostic with their lead investigational drug, AD04, for the treatment of alcohol use disorder and other drug dependencies. This patent expands Adial's intellectual property protection and opens up a significant market opportunity in the U.S. healthcare industry.
Adial Pharmaceuticals, un'azienda biomedica in fase clinica, ha ottenuto un brevetto chiave dall'Ufficio Brevetti e Marchi degli Stati Uniti. Il brevetto riguarda la combinazione del diagnostico genetico dell'azienda con il loro farmaco sperimentale principale, AD04, per il trattamento del disturbo da uso di alcol e altre dipendenze da droghe. Questo brevetto amplia la protezione della proprietà intellettuale di Adial e apre significative opportunità di mercato nel settore sanitario statunitense.
Adial Pharmaceuticals, una compañía biofarmacéutica en fase clínica, ha recibido una patente clave de la Oficina de Patentes y Marcas de los Estados Unidos. La patente cubre la combinación del diagnóstico genético de la compañía con su fármaco investigacional principal, AD04, para el tratamiento del trastorno por uso de alcohol y otras dependencias a drogas. Esta patente amplía la protección de propiedad intelectual de Adial y abre una importante oportunidad de mercado en la industria sanitaria de EE. UU.
임상 단계에 있는 생명공학 회사인 Adial Pharmaceuticals가 미국 특허청으로부터 중요한 특허를 획득하였습니다. 이 특허는 회사의 유전 진단과 주요 조사 약물인 AD04의 결합을 커버하며, 알코올 사용 장애와 다른 약물 의존성을 치료하기 위한 것입니다. 이 특허는 Adial의 지적 재산 보호를 확장하고 미국 의료 산업에서 중대한 시장 기회를 열어줍니다.
Adial Pharmaceuticals, une entreprise biopharmaceutique en phase clinique, a obtenu un brevet clé de l'Office des brevets et des marques des États-Unis. Le brevet couvre la combinaison du diagnostic génétique de l'entreprise avec leur médicament expérimental principal, AD04, pour le traitement des troubles liés à l'usage d'alcool et à d'autres dépendances aux drogues. Ce brevet étend la protection de la propriété intellectuelle d'Adial et ouvre des opportunités de marché significatives dans l'industrie de la santé aux États-Unis.
Adial Pharmaceuticals, ein biopharmazeutisches Unternehmen in der klinischen Phase, hat ein wichtiges Patent vom United States Patent and Trademark Office erhalten. Das Patent schützt die Kombination von Adials genetischer Diagnostik mit ihrem führenden Untersuchungsmedikament, AD04, zur Behandlung von Alkoholabhängigkeit und anderen Drogenabhängigkeiten. Dieses Patent erweitert den Schutz des geistigen Eigentums von Adial und eröffnet bedeutende Marktmöglichkeiten im US-Gesundheitswesen.
Positive
The grant of the patent strengthens Adial's position in the market by providing exclusive rights to their innovative genetic diagnostic and drug combination.
The patent covers the treatment of various addictive disorders, including alcohol use disorder and opioid use disorder, which have a combined market value of approximately $40 billion in the U.S. alone.
Adial's CEO, Cary Claiborne, highlighted the potential of the Company's personalized approach in offering new treatment options for millions of individuals affected by addiction and related disorders.
The patent signifies a major milestone for the Company in advancing their therapies for addiction treatment and prevention.
Negative
None.
GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11957664 was issued April 16, 2024 by the United States Patent and Trademark Office. This patent expands Adial’s intellectual property protection and covers the combination of the Company’s proprietary genetic diagnostic to identify patients with specific genotypes for genetically targeted treatment of alcohol use disorder (AUD) and other drug dependencies, such as opioid use disorder (OUD), with the Company’s lead investigational new drug product AD04.
Cary Claiborne, CEO of Adial, commented, “We are proud to have secured this new patent, which covers important aspects of the combination of our proprietary genetic diagnostic and AD04 to treat AUD, OUD, and other drug dependencies. Importantly, we have identified specific genotypes that have responded with clinically meaningful changes in drinking behavior compared to placebo in the AD04 post hoc analysis, which represents an addressable market of approximately $40 billion in the U.S. alone. We believe our unique personalized approach can offer new hope to the millions affected by AUD, OUD and other addictive disorders such as obesity and gambling.”
About Adial Pharmaceuticals, Inc. Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s companion diagnostic genetic test. ONWARD showed promising results in reducing drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com.
Forward-Looking Statements
This communication contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding the addressable market for AD04 representing approximately $40 billion in the U.S. alone, the Company’s unique personalized approach offering new hope to the millions affected by AUD, OUD and other addictive disorders such as obesity and gambling and the potential of AD04 to treat other addictive disorders such as opioid use disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to pursue our regulatory strategy, our ability to advance ongoing partnering discussions, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to develop strategic partnership opportunities and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to retain our key employees or maintain our Nasdaq listing, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statements included in our Annual Report on Form 10-K for the year ended December 31, 2023, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.
Contact: Crescendo Communications, LLC David Waldman / Alexandra Schilt Tel: 212-671-1020 Email: adil@crescendo-ir.com
FAQ
What is the patent number issued to Adial Pharmaceuticals by the United States Patent and Trademark Office?
Patent number 11957664 was issued to Adial Pharmaceuticals by the United States Patent and Trademark Office on April 16, 2024.
What does the patent cover for Adial Pharmaceuticals?
The patent covers the combination of Adial's proprietary genetic diagnostic with their lead investigational drug, AD04, for the treatment of alcohol use disorder and other drug dependencies.
Who commented on the issuance of the patent for Adial Pharmaceuticals?
Cary Claiborne, the CEO of Adial Pharmaceuticals, commented on the issuance of the patent and highlighted the importance of the Company's personalized approach in treating addiction and related disorders.
What market opportunity does the patent open up for Adial Pharmaceuticals?
The patent opens up a significant market opportunity in the U.S. healthcare industry for the treatment of alcohol use disorder, opioid use disorder, and other addictive disorders, with a combined market value of approximately $40 billion.
